Reduced Incidence

Related by string. * reduced . Reducing . reducer . REDUCED . REDUCING : reducing greenhouse gas . reducing carbon emissions . reducing CO2 emissions . reducing maternal mortality . Reduced Shakespeare Company / incidences . Incidences . incidence : colorectal cancer incidence . Colorectal cancer incidence . ERBITUX incidence . adverse reactions incidence . incidence ≥ * *

Related by context. Frequent words. (Click for all words.) 72 Patients Treated 70 Monotherapy 68 Combination Therapy 67 Phase III Trial 67 Heart Failure Patients 67 Pivotal Trial 67 Postmenopausal Women 66 Completes Enrollment 66 Clinical Trial Results 65 Tolerability 65 Randomized Controlled Trial 65 Pivotal Phase III 65 Chronic Hepatitis C 64 Acute Myocardial Infarction 64 Study Demonstrates 63 FDA Approves 63 Drug Candidate 63 Clinical Outcomes 63 Pivotal Phase 62 Prophylaxis 62 Meta Analysis 61 Enoxaparin 61 Subcutaneous 60 Low Dose 60 Bevacizumab 60 Solid Tumors 60 Infliximab 60 administered subcutaneously 59 Trastuzumab 59 Drug Eluting Stents 58 Irinotecan 58 Relapsed 58 Clopidogrel 58 C Reactive Protein 57 Gemcitabine 57 Efficacy 57 Immunogenicity 57 Nasal Spray 57 Stenting 57 Bortezomib 56 Adjuvant 56 Clinical Study 56 Inhibits 56 Myocardial Infarction 56 Pharmacokinetic 56 Coronary Stent 56 Rivaroxaban 56 Pioglitazone 55 Lenalidomide 55 Rosuvastatin 55 Initiates Phase 55 Laquinimod 54 Cisplatin 54 nab paclitaxel 54 Non Invasive 54 adalimumab 54 LIALDA 54 mg QD 53 Taxotere R 53 Prophylactic 53 Fidaxomicin 53 Small Molecule 53 Amrubicin 53 Drug Eluting Stent 53 Dexamethasone 52 Clinical Trial 52 Ezetimibe 52 Lantus R 52 Celecoxib 52 Voreloxin 52 azacitidine 52 Induces 51 tipranavir 51 Cost Effectiveness 51 double blinded placebo 51 Methotrexate 51 mcg kg 51 Pharmacokinetics 51 prospective observational 51 tocilizumab 51 FOLFIRI 51 plus methotrexate 50 Inhaled 50 Phase 1b trial 50 HGS ETR1 50 certolizumab pegol 50 prospective randomized controlled 50 SCH # 50 Randomized Trial 50 active comparator 50 Main Outcome Measures 50 Endpoints 50 mg BID 50 Phase 1b 50 Ribavirin 50 Dermal 50 decitabine 49 multicenter randomized double 49 randomized controlled clinical 49 Phase III randomized 48 Potency

Back to home page